References

Duarte-Díaz A, Perestelo-Pérez L, Gelabert E, Robles N, Pérez-Navarro A, Vidal-Alaball J, Solà-Morales O, Sales Masnou A, Carrion C Efficacy, safety, and evaluation criteria of mHealth interventions for depression: systematic review. JMIR Ment Health. 2023; 10 https://doi.org/10.2196/46877

Fava M The challenges of defining and managing treatment-resistant depression in research and practice. World Psychiatry. 2023; 22:(3)350-351 https://doi.org/10.1002/wps.21128

Khabir Y, Hashmi MR, Ali Asghar A Rapid-acting oral drug (Auvelity) for major depressive disorder. Ann Med Surg (Lond). 2022; 82 https://doi.org/10.1016/j.amsu.2022.104629

Maina G, Adami M, Ascione G, Bondi E, De Berardis D, Delmonte D, Maffezzoli S, Martinotti G, Nivoli A, Ottavianelli E Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel. Ann Gen Psychiatry. 2023; 22:(1) https://doi.org/10.1186/s12991-023-00478-7

Mancuso E, Sampogna G, Boiano A, Della Rocca B, Di Vincenzo M, Lapadula MV, Martinelli F, Lucci F, Luciano M Biological correlates of treatment resistant depression: a review of peripheral biomarkers. Front Psychiatry. 2023; 14 https://doi.org/10.3389/fpsyt.2023.1291176

McCarthy B, Bunn H, Santalucia M, Wilmouth C, Muzyk A, Smith CM Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder. Clin Psychopharmacol Neurosci. 2023; 21:(4)609-616 https://doi.org/10.9758/cpn.23.1081

McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023; 22:(3)394-412 https://doi.org/10.1002/wps.21120

National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline [NG222]. 2022. https://www.nice.org.uk/guidance/ng222 (accessed 24 October 2024)

Oliveira-Maia AJ, Bobrowska A, Constant E, Ito T, Kambarov Y, Luedke H, Mulhern-Haughey S, von Holt C Treatment-resistant depression in real-world clinical practice: A systematic literature review of data from 2012 to 2022. Adv Ther. 2024; 41:(1)34-64 https://doi.org/10.1007/s12325-023-02700-0

Watson K, Akil H, Rasgon N Toward a precision treatment approach for metabolic depression: integrating epidemiology, neuroscience, and psychiatry. Biological Psychiatry Global Open Science. 2023; 3:(4)623-631 https://doi.org/10.1016/j.bpsgos.2023.08.008

Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, Zhao J, Liu Y, Fang Y, Zhang Y, Xie P Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. Int J Neuropsychopharmacol. 2015; 18:(11) https://doi.org/10.1093/ijnp/pyv060

A novel antidepressant intervention for outpatient psychiatry

02 February 2025
Volume 7 · Issue 2

Abstract

This article explores the potential of the novel antidepressant dextromethorphan-bupropion in addressing treatment-resistant depression (TRD). Traditional approaches, including selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors, alongside antipsychotic agents, often prove insufficient. Amid a global surge in TRD post-COVID-19, dextromethorphan-bupropion emerges as an effective treatment option for a subset of 52 patients. Results indicated 27 patients experienced improvement within 2 weeks and 43 achieved remission after 2 months of dextromethorphan-bupropion use. While acknowledging limitations, particularly in a medically under-served demographic, this article advocates for the integration of novel antidepressants into TRD management guidelines. Caution must be exercised given the small sample size; however, dextromethorphan-bupropion stands as a promising therapeutic cornerstone offering renewed hope to those navigating the challenging terrain of TRD and prompting broader discussions for future collaborative research.

In the realm of mental health, the persistent challenge of treatment-resistant depression (TRD) has led to a search for innovative solutions (Fava, 2023; Maina et al, 2023; Mancuso et al, 2023; Oliveira-Maia et al, 2024). For those who have tried at least two conventional antidepressants and found little respite in the augmentation of antipsychotic agents, the exploration of novel interventions becomes critical. In this context, dextromethorphan-bupropion emerges as an effective treatment option for those treating TRD (McCarthy et al, 2023).

Traditional therapeutic approaches often prove insufficient in alleviating depressive symptoms in these patients, underscoring the urgent need for a shift towards novel and transformative strategies (Duarte-Díaz et al, 2023; Watson et al, 2023). Dextromethorphan-bupropion, with its distinctive pharmacological profile and mechanism of action, has captured the attention of the psychiatric community as a potential option in the landscape of depression treatment (Khabir et al, 2022).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month